U.S. Markets open in 6 hrs 47 mins

Pacira Pharmaceuticals, Inc. (PCRX)

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
41.625-1.025 (-2.403%)
At close: 4:00PM EDT
People also watch
SUPNPTLAIRWDCLVSPTCT
Full screen
Previous Close42.650
Open42.450
Bid0.000 x
Ask0.000 x
Day's Range41.475 - 43.000
52 Week Range29.950 - 58.950
Volume1,520,229
Avg. Volume664,212
Market Cap1.67B
Beta2.11
PE Ratio (TTM)-28.89
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • SmarterAnalyst12 hours ago

    Pacira Pharmaceuticals Inc (PCRX) and EXACT Sciences Corporation (EXAS) Are Shaking Up the Market

    Pacira Pharmaceuticals Inc (NASDAQ:PCRX) shares were falling 12% yesterday after the drug maker's pain medicine failed to meet a primary efficacy endpoint in one of its two Phase 3 femoral nerve block trial. As far as Davis sees it, Pacira is still "moving on to the finals," having just the right data to deliver a response to the FDA's Complete Response Letter (CRL) from back in March 2015. In other words, the drug maker will soon be re-filing its sNDA in the indication of nerve block.

  • Pacira Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : PCRX-US : July 26, 2017
    Capital Cube17 hours ago

    Pacira Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : PCRX-US : July 26, 2017

    Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Pacira Pharmaceuticals, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average Bullish ... Read more (Read more...)

  • Why Pacira Pharmaceuticals Shares Are Crashing 15% Today
    Motley Fool2 days ago

    Why Pacira Pharmaceuticals Shares Are Crashing 15% Today

    Disappointing late-stage trial data is dashing investor optimism.